An exploratory clinical study of islet-like cell transplantation differentiated from autologous induced pluripotent stem cells for the treatmen of type 1 diabetes

Start Date11 Jun 2023

Sponsor / Collaborator

Tianjin First Center Hospital

NCT05647213 / RecruitingPhase 1

Safety and Feasibility of Autologous Induced Pluripotent Stem Cells of Cardiac Lineage in Subjects With Congenital Heart Disease

The goal of this clinical trial is to test the safety of lab-grown heart cells made from stem cells in subjects with congenital heart disease. The main questions it aims to answer are:
Is this product safe to deliver to humans
Is the conduct of this trial feasible
Participants will be asked to:
Agree to testing and monitoring before and after product administration
Receive investigational product
Agree to lifelong follow-up Researchers will compare subjects from the same pool to see if there is a difference between treated and untreated subjects.

Start Date03 Feb 2023

Sponsor / Collaborator

HeartWorks

100 Clinical Results associated with Autologous Induced Pluripotent Stem Cells(HeartWorks, Inc.)

100 Translational Medicine associated with Autologous Induced Pluripotent Stem Cells(HeartWorks, Inc.)

100 Patents (Medical) associated with Autologous Induced Pluripotent Stem Cells(HeartWorks, Inc.)

Literatures (Medical) associated with Autologous Induced Pluripotent Stem Cells(HeartWorks, Inc.)

01 Jul 2017·Bioorganic & Medicinal Chemistry LettersQ4 · MEDICINE

Quorum sensing modulators exhibit cytotoxicity in Hodgkin’s lymphoma cells and interfere with NF-κB signaling

Q4 · MEDICINE

Article

Author: Gopas, Jacob ; Nandakumar, Natarajan ; Meijler, Michael M ; Dandela, Rambabu

In recent years it has become evident that bacteria can modulate signaling pathways in host cells through the secretion of small signaling molecules. We have evaluated the cytotoxic effects and NF-κB inhibitory activities of a panel of quorum sensing molecules and their reactive analogs on Hodgkin's lymphoma cells (L428). We found that several molecules inhibited NF-κB signaling in a dose dependent manner. Three inhibitors (ITC-12, ITC-Cl and Br-Furanone) showed 50% NF-κB inhibition at concentrations less than 10µM (4.1µM, 12.8µM and 9.9µM, respectively). Furthermore, all three molecules displayed cytotoxic effects against L428 cells with IC50 values of 12.4µM, 18.3µM and 3.1µM respectively after 48h incubation. They also showed inhibition of A549 adenocarcinoma cell migration at low concentrations 5.6µM, 2.6µM and 7.9µM respectively. Further analysis showed that these molecules significantly decrease the degree of expression of proteins of NF-κB subunits p50, p65 and RelB both in cytosolic and nuclear fractions. This confirms that these compounds have the potential to modulate the NF-κB pathway by suppressing their subunits and thus exhibit cytotoxicity and inactivation of NF-κB signaling in Hodgkin's lymphoma cells.

01 Dec 1984·Cancer Immunology ImmunotherapyQ2 · MEDICINE

Antitumor and therapeutic effects of spleen cells from tumor-bearing mice cultured with T cell growth factor and soluble tumor extract

Q2 · MEDICINE

Article

Author: Norimichi Kan ; Hiroshi Kodama ; Takashi Inamoto ; Kazuhisa Ohgaki

Spleen cells of BALB/c mice that had been inoculated with syngeneic plasmacytoma MOPC 104E were cultured for 11 days in T-cell growth factor (TCGF) and ultrasonicated tumor extract (USE). Cultured lymphocytes (MOPC-CL) possessed three-fold more lytic units than normal spleen cells cultured in TCGF without USE (N-CL). Moreover, the in vivo neutralization assay suggested that MOPC-CL were composed of at least two populations, one possessing tumor-specific and the other nonspecific antitumor activity. When 2 X 10(7) of MOPC-CL were administered IP to mice that had been inoculated IP with 10(5) MOPC 104E cells 5 days previously marginal prolongation of survival was observed. This effect was not augmented by the single injection of a larger number (5 X 10(7] of CL, but was augmented by the repeated daily administration for 4 days (from day 5 to day 8 after the inoculation) of the same total number (5 X 10(7] of CL. In addition, IP injection of the streptococcal preparation OK432 before the transfer of CL significantly enhanced the therapeutic efficacy, and resulted in a cure rate of 20%. The mechanism of this combined effect appears to involve the effect of OK432 on interleukin 2 (IL-2) regulation systems in vivo. Our culture system with TCGF and USE and our therapy system with OK432 and CL allow the clinical application of adoptive immunotherapy for the many types of solid cancers.

100 Deals associated with Autologous Induced Pluripotent Stem Cells(HeartWorks, Inc.)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Heart failure NYHA class III	Phase 1	US	HeartWorks	03 Feb 2023
Heart failure NYHA class IV	Phase 1	US	HeartWorks	03 Feb 2023
Univentricular Heart	Phase 1	US	HeartWorks	03 Feb 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Autologous Induced Pluripotent Stem Cells(HeartWorks, Inc.)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation